Analysis for TMO
- 📈 Growth — 22/30
- 💰 Profitability — 17/20
- 🏦 Financial Health — 18/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 4/10
Summary:
📈 Growth & Financial Trajectory
Over the 8 quarters from 2024 Q2 to 2026 Q1, Revenues rose modestly from about $10.54B to about $11.01B, a gain of roughly 4-5%. Net income improved from about $1.56B to $1.66B, with a pronounced peak in 2025 Q4 near $1.96B before a small dip in 2026 Q1, indicating steady but not accelerating profitability.
💰 Margins & Cash Flow
Operating margins remained in the mid-teens (roughly 15-18%), signaling healthy operating leverage for a large cap. Cash flow from operations stayed positive across quarters; investing outflows were sizable in several periods, leading to fluctuations in overall free cash flow despite strong operational cash generation.
🛡️ Balance Sheet & Liquidity
Balance sheet strength is solid: assets around $100-110B, Equity near $49-53B, and a durable current ratio around ~1.5x. Long-term debt ranged in the mid-30s to mid-40s billions, but liquidity remains ample to fund capex and pipeline investments.
⚠️ Key Drivers & Risks
- Drivers: Life sciences R&D and bioprocessing investment; pharma/biotech outsourcing and ongoing lab diagnostics demand.
- Risks: Budget cyclicality in healthcare/life sciences; currency and input-cost volatility; valuation sensitivity to growth expectations.